Irnocam 40mg (Irinotecan)

Description of Irnocam 40mg (Irinotecan 40mg)

Irnocam 40mg (Irinotecan 40mg) is a camptothecin derivative that exerts antitumor activity against a variety of tumors.The active metabolite of Campto is SN-38 produced in the body by carboxylesterase .

Irnocam 40mg (Irinotecan 40mg) is used to cure cancers of the colon and rectum. It is usuallyadministering with other chemotherapy medicines in a combination chemotherapy.

Irnocam 40mg (Irinotecan 40mg) is a prescription medicine which is used under supervision by medical physician

Medical use /Indication of Irnocam 40mg (Irinotecan 40mg)

Irnocam 40mg (Irinotecan 40mg) is mainly used for the treatment in patients with metastatic colon or rectal cancer.

Mechanism of Action Irnocam 40mg (Irinotecan 40mg)

Camptothecin is a derivative of irinotecan which interact particularly with the enzyme topoisomerase I, which relieves torsional strain in DNA by activating reversible single-strand breaks. Irinotecan and its active metabolite SN-38 bind to the topoisomerase I-DNA complex and inhibitsrelocation of these single-strand breaks. The cytotoxicity of Irinotecan is because of double-strand DNA injury produced during DNA combination when multiplication enzymes interact with the ternary complex formed by topoisomerase I, DNA, and either Irinotecan or SN-38. Mammalian cells cannot expertly repair these double strand breaks.

Absorption of Irnocam 40mg (Irinotecan 40mg)

Irnocam 40mg (Irinotecan 40mg) has time to Peak Plasma Concentration of Irnocam 40mg (Irinotecan 40mg) is 1660 ng/mL; SN-38 26.3 ng/mL

Distribution of Irnocam 40mg (Irinotecan 40mg)

Irnocam 40mg (Irinotecan 40mg) has Protein Bound: 30-68%; SN-38 95% and Vd: 110-234 L/m²

Metabolism of Irnocam 40mg (Irinotecan 40mg)

Irnocam 40mg (Irinotecan 40mg) is mainly metabolized in hepatic, to SN-38; SN-38 is further metabolized by UGT1A1 and metabolites are metabolized to SN-38

Excretion of Irnocam 40mg (Irinotecan 40mg)

Excretion of Irnocam 40mg (Irinotecan 40mg) through urine, feces

Half-Life of Irnocam 40mg (Irinotecan 40mg): 6-12 hr; SN-38 10-20 hr

Side effects of Irnocam 40mg (Irinotecan 40mg)

Common side effects of Irnocam 40mg (Irinotecan 40mg) :

Anxiety, Black, tarry stools, Changes in skin colour, Bruising, Chest pain, Decrease appetite, Confusion, Constricted pupils, Hoarseness, Dark urine , Hair loss, Mouth ulcers, Tummy pain.

Serious side effects of Irnocam 40mg (Irinotecan 40mg) :

Decreased amount of urine, Troubled breathing, Hives , Rapid weight gain, Constipation, Liver changes, Increased blood pressure, Swelling around the drip site, Skin rash, Dizziness, Blood clots.

Precautions of Irnocam 40mg (Irinotecan 40mg)

Medicine Irnocam 40mg (Irinotecan 40mg) is exposed to photodegradation, specifically in neutral & alkaline solutions

When treatment will cause Hyperbilirubinemia, elderly, receiving radiation therapy, abdominal/pelvic radiation history

Not for use in concomitant with a regimen of 5-FU/LV administered for 4-5 consecutive days every 4 weeks outside of a clinical study

While on Irnocam 40mg (Irinotecan 40mg) treatment interstitial pulmonary disease (IPD)-like events, contains fatalities, have been resulted (in combination and as monotherapy) for treatment of colorectal cancer and other advanced solid tumors

Risk of both early and late forms of diarrhea will occurs on treatment with Irnocam 40mg (Irinotecan 40mg)

Risk of serious myelosuppression; manage febrile neutropenia immediately with antibiotic support; discontinue therapy and decrease subsequent doses if necessary

Drug interaction of Irnocam 40mg (Irinotecan 40mg)

• When interaction of Irnocam 40mg (Irinotecan 40mg)with 5-fluorouracil and leucovorin (LV), the disposition of irinotecan was not substantially altered.
• Co administration of Irnocam 40mg (Irinotecan 40mg)with strong CYP34A inducers do not administer unless there are no therapeutic alternatives
• When concomitant use of Irnocam 40mg (Irinotecan 40mg) with strong CYP34A inhibitors may increase systemic exposure to irinotecan or SN-38

Contraindication of Irnocam 40mg (Irinotecan 40mg)

Irnocam 40mg (Irinotecan 40mg) contraindicated in patients with known hypersensitivity to the medicine or its excipients

Pregnancy of Irnocam 40mg (Irinotecan 40mg)

Pregnancy category is D

The medicine Irnocam 40mg (Irinotecan 40mg) may causes risk to fetus when administered to pregnant women. Advice the women about the potential hazard to the fetus

Lactation of Irnocam 40mg (Irinotecan 40mg)

The medicine Irnocam 40mg (Irinotecan 40mg) has no data on the excretion into human milk. Advice the breastfeed mother potential risk to the infants. So, discontinue nursing when getting treatment with Campto.

Dosage of Irnocam 40mg (Irinotecan 40mg)

Colorectal cancer :

Monotherapy dosage :

Premediate the patients with antiemetic agents

For experience cholinergic symptoms in patient’s atropine treatment should be considered

Dose 1: 125mg/m2 IV infusion over 90 minutes on days 1,8,15,22, then 2 weeks off then repeat administrated weekly Dose 2: 350mg/sq. meter IV Infusion over 30-90 minutes q3weeks administrated once every 3 weeks.

Combination therapy :

Premediate the patients with antiemetic agents

For experience cholinergic symptoms in patient’s atropine treatment should be considered

Dose 1: 180mg/m2 IV infusion over 30-90 minutes once on days 1,15, and 29, then followed by infusion with leucovorin and 5- fluorouracil; next cycle begins on day 43

Dose 2: 125mg/sq. meter on days 1,8,15 and 22 IV Infusion over 90 minutes then followed by bolus doses of leucovorin and 5-fluorouracil

Storage of Irnocam 40mg (Irinotecan 40mg)

Irnocam 40mg (Irinotecan 40mg) is Store at 20℃ to 25 ℃

Protect from light

Keep in its original vial until the time of use

Missed dose of Irnocam 40mg (Irinotecan 40mg)

If dose is missed, then take the dose immediately before reach of next dose time or leave the missed dose and follow the normal schedule. Avoid have extra dose which leads to over dosage

Consult the doctor about missed dose and overdose